Esperion Therapeutics Reports Routine Director Option Grant

Q: What did ESPR disclose in its latest Form 4?

A director was granted 40,000 stock options at a $1.00 exercise price on 07/01/2025.

Q: When do the ESPR options granted to John Craig Thompson vest?

They vest in three equal annual installments, beginning July 1, 2026 and ending July 1, 2028.

Q: What is the exercise price and expiry of the new ESPR options?

The exercise price is $1.00 per share and the options expire on July 1, 2035 .

Q: Does the Form 4 indicate any ESPR common stock purchases or sales?

No. The filing only reports an option grant ; no common shares were bought or sold.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Esperion Therapeutics (ESPR) – Form 4 filing: On 07/01/2025 director John Craig Thompson received an option grant for 40,000 shares of common stock at an exercise price of $1.00 per share. The options vest in three equal annual installments beginning 07/01/2026 and expire on 07/01/2035. No common shares were bought or sold; the transaction is classified as an "A" (grant) and the beneficial ownership is reported as direct. Following the grant, Thompson beneficially owns 40,000 derivative securities (options) and no change was reported in non-derivative share ownership.

Positive

Multi-year vesting schedule encourages long-term alignment between the director and shareholders.

Negative

No open-market share purchase; the filing does not convey additional insider conviction and introduces a small potential dilution of 40,000 shares.

Insights

TL;DR: Routine option grant to director; aligns incentives, minimal dilution, neutral financial impact.

The Form 4 discloses a standard equity incentive: 40,000 stock options at a nominal $1.00 strike, vesting over three years. Such awards are typical for board members of development-stage biopharma companies and help align director interests with long-term shareholder value. The grant represents a small fraction of Esperion’s outstanding shares, therefore no material dilution or immediate cash movement occurs. Because the transaction is a compensation grant rather than an open-market purchase, it offers limited signalling value regarding management’s view of near-term share price. Overall, the filing is governance-routine and financially immaterial.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider THOMPSON JOHN CRAIG

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 40,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

07/02/2025 - 08:21 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

THOMPSON JOHN CRAIG

(Last)

(First)

(Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR

48108

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1	07/01/2025		A		40,000		⁽¹⁾	07/01/2035	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The awards vest over a three (3) year period in equal annual installments the first of which will be July 1, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ESPR disclose in its latest Form 4?

A director was granted 40,000 stock options at a $1.00 exercise price on 07/01/2025.

When do the ESPR options granted to John Craig Thompson vest?

They vest in three equal annual installments, beginning July 1, 2026 and ending July 1, 2028.

What is the exercise price and expiry of the new ESPR options?

The exercise price is $1.00 per share and the options expire on July 1, 2035.

Does the Form 4 indicate any ESPR common stock purchases or sales?

No. The filing only reports an option grant; no common shares were bought or sold.